Astellas Advagraf® XL Patient Program

In April 2018, Kos designed, developed, and implemented the Advagraf® XL Patient Program with Astellas Pharma Australia Pty. Ltd. and in partnership with PharmaPrograms. Advagraf® XL is a once-daily prolonged-release tacrolimus, an immunosuppressive agent indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.